Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial

BACKGROUND: In the ROCKET AF (Rivaroxaban–Once‐daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Daniel E., Hellkamp, Anne S., Yuan, Zhong, Lokhnygina, Yuliya, Patel, Manesh R., Piccini, Jonathan P., Hankey, Graeme J., Breithardt, Günter, Halperin, Jonathan L., Becker, Richard C., Hacke, Werner, Nessel, Christopher C., Mahaffey, Kenneth W., Fox, Keith A. A., Califf, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392426/
https://www.ncbi.nlm.nih.gov/pubmed/25736441
http://dx.doi.org/10.1161/JAHA.114.001349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392426/
https://www.ncbi.nlm.nih.gov/pubmed/25736441
http://dx.doi.org/10.1161/JAHA.114.001349

Ejemplares similares